Serum elevations of soluble Fas (CD95/Apo-I) concur in deregulating T cell apoptosis during active lupus disease

Clinical and Experimental Medicine

Volumn 2, Issue 1, 2002, Pages 13-27

  Silvestris, F ^a   Williams, R C ^b   Calvani, N ^a   Grinello, D ^a   Tucci, M ^a   Cafforio, P ^a   Dammacco, F ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; CPP32; Metalloproteases; Poly (ADP) ribose polymerase; sFas

Indexed keywords

FAS ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P26; PROTEIN P48; UNCLASSIFIED DRUG; CASPASE; CD3 ANTIGEN; EPITOPE; ISOPROTEIN;

APOPTOSIS; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEREGULATION; DISEASE ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INCUBATION TIME; MEASUREMENT; PLOIDY; PRIORITY JOURNAL; PROTEIN SECRETION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; BLOOD; CELL CULTURE; CYTOLOGY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; METABOLISM; MITOCHONDRION; NICK END LABELING; PHYSIOLOGY;

ANTIGENS, CD3; ANTIGENS, CD95; APOPTOSIS; CASPASES; CELLS, CULTURED; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN ISOFORMS; T-LYMPHOCYTES;

EID: 0036019536     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s102380200002     Document Type: Article

References (54)

1. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus
2. The key role of nucleosomes in lupus
3. Nucleosomes: A major immunogen for pathogenic autoantibody inducing T cells of lupus
4. Phagocyte recognition of cells undergoing apoptosis
5. The polypeptide encoded by the cDNA for human surface antigen Fas can mediate apoptosis
6. The apoptosis-1/Fas protein in human systemic lupus erythematosus
7. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): A possible mechanism for lymphopenia
8. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases
9. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
10. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
11. Soluble Fas (Apo-1, CD95) and soluble Fas ligand in rheumatic diseases
12. Lymphocyte apoptosis in systemic lupus erythematosus: Relationship with Fas expression, serum soluble Fas and disease activity
13. An N-terminal domain shared by Fas/Apo-I (CD95) soluble variants prevents cell death in vitro
14. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
15. Autoimmune disease. A problem of defective apoptosis
16. Lack of correlation between serum soluble Fas/Apo-1 levels and autoimmune disease
17. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons
18. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse
19. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus
20. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
21. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic lymphocytes
22. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection
23. Evaluation of soluble necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease
24. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor
25. Fas pre-association required for apoptosis signaling and dominant inhibition by pathogenic mutations
26. Anti-Fas (CD95/Apo-I) autoantibodies and soluble Fas levels concur in T cell depletion in HIV-1 infection
27. The 1982 revised criteria for the classification of systemic lupus erythematosus
28. Derivation of SLEDAI. A disease activity index for lupus patients
29. + lymphopenia
30. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
31. + cells by the hydroxylamide of sulphamethoxazole
32. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: Differential ligation constantly induces apoptosis
33. Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7
34. Immunocytochemical detection and mapping of a cytocheratin 18 neo-epitope exposed during early apoptosis
35. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease
36. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines
37. Apoptosis and expression of soluble Fas mRNA in systemic lupus erythematosus
38. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus
39. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases
40. Cytokines and systemic lupus erythematosus
41. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes
42. Increased caspase-3 like activity in freshly isolated lymphocytes from SLE patients
43. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis
44. Serum levels of soluble Fas/Apo-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
45. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus
46. Self-association of the "death domain" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO-1 prompts signaling for TNF and Fas/APO-1 effects
47. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling
48. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: Relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells
49. A matrix metalloproteinase gene expressed in human T lymphocytes is identical with collagenase 3 from breast carcinomas
50. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis
51. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1)
52. Increased serum pro-MMP-3 in inflammatory arthritides: A potential indicator of synovial inflammatory monokine activity
53. Circulating levels of matrix metalloproteinase MMP-3 and MMP-1, tissue inhibitor of metalloproteinase 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
54. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis